Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brepocitinib in skin-predominant dermatomyositis
NCT06433999Phase 2Completed
- Sponsor
- Priovant Therapeutics
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brepocitinib in dermatomyositis (DM), sponsored by Priovant Therapeutics. Primary endpoint: Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score at 12 weeks. Started Aug 2024; status: completed.
02
Drugs
brepocitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06433999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433999.